Twitter | Search | |
Erin D. Michos, M.D.
Director of Women's CV Health, Johns Hopkins School of Medicine. Associate Professor. Preventive Cardiology & Adult Echo. She/her. Tweets are my own.
20,939
Tweets
7,203
Following
14,215
Followers
Tweets
Erin D. Michos, M.D. retweeted
Shelley Zieroth 2h
Good lighting, good powder and Great discussants is a girls BF !!
Reply Retweet Like
Erin D. Michos, M.D. 6h
And also a shout-out to the new members of the team in the past year - the very talented & residents, and Johns Hopkins medical students doing projects in . So happy to work with you! 👏👏👏
Reply Retweet Like
Erin D. Michos, M.D. 6h
On Fri faculty gave presentations to the fellows about their research labs to introduce research in our division. Putting together my slides I wanted to give a big shout-out to all the fabulous talented trainees who I've had the great honor to work with. 🌟
Reply Retweet Like
Erin D. Michos, M.D. 8h
Spectacular, !
Reply Retweet Like
Erin D. Michos, M.D. 9h
Replying to @ErinMichos
Take 2: Typo in Bill's last name, now corrected, lol.
Reply Retweet Like
Erin D. Michos, M.D. 9h
Thank you and for your great recent perspective in . I am giving an upcoming talk on for , and now I have a fun new slide to include!
Reply Retweet Like
Erin D. Michos, M.D. retweeted
Ugo O. Egolum, MD FACC 12h
More evidence as to the clinical impact of sglt2i therapy. ~30% reduction in HHF. ~14% reduction in (all cause and cardiac) mortality. ~40% reduction in renal composite outcomes. Excellent safety profile. No excuses. GDMT saves lives! Bb+arni+mra+sglt2i is first line therapy!
Reply Retweet Like
Erin D. Michos, M.D. 12h
Reply Retweet Like
Erin D. Michos, M.D. retweeted
Shelley Zieroth 13h
Replying to @ErinMichos
Thanks !! Loved your commentary yesterday.
Reply Retweet Like
Erin D. Michos, M.D. 12h
Reply Retweet Like
Erin D. Michos, M.D. 12h
Congratulations on your award. Truly well deserved. I also appreciate your generosity of spirit, for recognizing that science is built on collaboration and not individualism. You represent what is good in academic medicine and I am grateful to be among your circle.
Reply Retweet Like
Erin D. Michos, M.D. 13h
Congrats and the whole team. 👏👏👏
Reply Retweet Like
Erin D. Michos, M.D. 14h
How has the pattern of autopsies conducted for CVD changed over past 15 years among demographic subgroups? Find out in this latest study by .
Reply Retweet Like
Erin D. Michos, M.D. 16h
Beautiful piano 🎹
Reply Retweet Like
Erin D. Michos, M.D. retweeted
Shelley Zieroth 17h
Replying to @BiykemB @ErinMichos
caught a group photo . Thank u for your support!
Reply Retweet Like
Erin D. Michos, M.D. 16h
We also wrote a similar comparison earlier this year, published in Mayo Clinic Proceeding: "Comparison of Transatlantic Approaches to Lipid Management: The AHA/ACC/Multisociety Guidelines vs the ESC/EAS Guidelines"
Reply Retweet Like
Erin D. Michos, M.D. retweeted
Chadi Alraies, MD FACC 18h
Excellent work by and team on causes of admissions and mortality pleasure to work with this phenomenal team
Reply Retweet Like
Erin D. Michos, M.D. retweeted
ALEXANDRU MISCHIE Oct 22
Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries (EAPCI & ESC Working Group on Coronary Pathophysiology & Microcirculation)
Reply Retweet Like
Erin D. Michos, M.D. retweeted
Muthu Vaduganathan Oct 23
Effect of Finerenone on Chronic Kidney Disease Outcomes in T2D Landmark & highly anticipated presented at & pub in . In CKD+T2D, 18% lower risk of kidney progression & 14% lower risk of 3p-MACE+HF events w finerenone vs PBO.
Reply Retweet Like
Erin D. Michos, M.D. 20h
Reply Retweet Like